<p>Alport syndrome is a rare genetic disorder characterized by abnormalities of the inner ear and the eye. The disease is caused by an inherited defect in type IV collagen, a structural material needed for the normal function of different body parts. Alport syndrome can present itself in many forms. This includes X-linked Alport syndrome (XLAS), autosomal recessive Alport syndrome (ARAS), and autosomal dominant Alport syndrome (ADAS). Clinically, it is associated with microscopic hematuria, followed by proteinuria and chronic renal insufficiency with end-stage renal disease in young adults.&nbsp;</p>
<h2><a href="https://www.delveinsight.com/report-store/alport-syndrome-epidemiology-forecast"><span style="text-decoration: underline;"><strong>Alport Syndrome Epidemiology</strong></span></a></h2>
<ul>
<li>The total number of prevalent cases of Alport syndrome in the 7MM were approximately ~159K in 2023.</li>
<li>Alport syndrome is more prevalent in the adult population, accounting for ~86% of the cases in the 7MM, while the pediatric population makes up ~14% of cases.</li>
<li>X-linked Alport syndrome (XLAS) is the most prevalent subtype, with around 11K cases in the US in 2023, while autosomal dominant Alport syndrome (ADAS) is the least prevalent.</li>
<li>In the EU4 region, Germany had the highest number of Alport syndrome cases, with nearly 17K cases in 2023, while Spain reported the fewest cases.</li>
</ul>
<h2><a href="https://www.delveinsight.com/report-store/alport-syndrome-market"><span style="text-decoration: underline;"><strong>Alport Syndrome Market</strong></span></a></h2>
<p>The Alport Syndrome market size in the 7MM was&nbsp; ~USD 20 million in 2023.</p>
<h2>Alport Syndrome Market Drivers:</h2>
<ul>
<li>Growing understanding of the genetic basis and disease pathophysiology.</li>
<li>Rising prevalence of genetic testing and early diagnosis.</li>
<li>Increased research into targeted therapies and gene therapy.</li>
<li>Strong unmet need for disease-modifying treatments and long-term management.</li>
</ul>
<h2>Alport Syndrome Market Barriers:</h2>
<ul>
<li>Limited awareness and misdiagnosis, delaying treatment.</li>
<li>Lack of approved therapies for Alport syndrome.</li>
<li>High treatment costs for rare genetic disorders.</li>
<li>Challenges in genetic testing and early diagnosis in underdiagnosed populations.</li>
</ul>
<h2><a href="https://www.delveinsight.com/report-store/alport-syndrome-pipeline-insight"><span style="text-decoration: underline;"><strong>Alport Syndrome Emerging Drugs</strong></span></a></h2>
<ul>
<li>ELX-02</li>
<li>Atrasentan</li>
</ul>
<p>And others.&nbsp;</p>
<h2><strong>Alport Syndrome Key Players</strong></h2>
<ul>
<li>Eloxx Pharmaceuticals</li>
<li>Chinook Therapeutics</li>
<li>Novartis</li>
<li>Bayer</li>
<li>Calliditas Therapeutics</li>
<li>Evotec</li>
</ul>
<p>And others.</p>

Alport Syndrome Market Infographic

Alport Syndrome Market Size, Forecast Infographics

Alport Syndrome Symptoms, Treatment, epidemiology, companies, drugs infographic is a short guide to understand the problem and market landscape.